Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease

STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases of classical Hodgkin's disease. Prolifer...

Descripción completa

Detalles Bibliográficos
Autores principales: Re, D, Wickenhauser, C, Ahmadi, T, Buchdunger, E, Kochanek, M, Diehl, V, Wolf, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375346/
https://www.ncbi.nlm.nih.gov/pubmed/11953894
http://dx.doi.org/10.1038/sj.bjc.6600243
Descripción
Sumario:STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases of classical Hodgkin's disease. Proliferation of L1236 cells was neither affected by addition of stem cell factor nor by neutralising anti-stem cell factor antibodies or STI571. Results suggest that patients with Hodgkin's disease may not benefit from therapy with STI571. British Journal of Cancer (2002) 86, 1333–1335. DOI: 10.1038/sj/bjc/6600243 www.bjcancer.com © 2002 Cancer Research UK

Ejemplares similares